Formatted: Left: 1", Right: 1", Width: 11", Height: 8.5"

Table S1. Summary of Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term During the Double-Blind Treatment Period – Safety Population

System organ class Preferred term	Placebo (N = 71) n (%)	MSDC-0160 50 mg (N = 71) n (%)	MSDC-0160 100 mg (N = 71) n (%)	MSDC-0160 150 mg (N = 70) n (%)	Pioglitazone 45 mg (N = 71) n (%)	Total (N = 354) n (%)
Nervous system disorders	1 (1.4)	2 (2.8)	3 (4.2)	1 (1.4)	2 (2.8)	9 (2.5)
Headache	1 (1.4)	1 (1.4)	2 (2.8)	0 (0.0)	1 (1.4)	5 (1.4)
Dizziness	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (1.4)	2 (0.6)
Balance disorder	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Lethargy	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	1 (0.3)
Gastrointestinal disorders	2 (2.8)	1 (1.4)	0 (0.0)	0 (0.0)	1 (1.4)	4 (1.1)
Diarrhea	1 (1.4)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.6)
Constipation	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Dyspepsia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	1 (0.3)
Nausea	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	1 (0.3)
General disorders and administration site conditions	0 (0.0)	1 (1.4)	1 (1.4)	2 (2.9)	0 (0.0)	4 (1.1)
Edema peripheral	0 (0.0)	0 (0.0)	1 (1.4)	2 (2.9)	0 (0.0)	3 (0.8)
Feeling cold	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Investigations	1 (1.4)	1 (1.4)	1 (1.4)	1 (1.4)	0 (0.0)	4 (1.1)
Alanine aminotransferase increased	0 (0.0)	0 (0.0)	1 (1.4)	1 (1.4)	0 (0.0)	2 (0.6)
Aspartate aminotransferase increased	0 (0.0)	0 (0.0)	1 (1.4)	1 (1.4)	0 (0.0)	2 (0.6)
Blood uric acid decreased	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Heart rate increased	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Musculoskeletal and connective tissue disorders	0 (0.0)	0 (0.0)	2 (2.8)	1 (1.4)	1 (1.4)	4 (1.1)
Arthralgia	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Back pain	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	1 (0.3)
Muscle spasms	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	1 (0.3)
Myalgia	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Pain in extremity	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Skin and subcutaneous tissue disorders	0 (0.0)	1 (1.4)	1 (1.4)	1 (1.4)	1 (1.4)	4 (1.1)
Eczema	0 (0.0)	1 (1.4)	0 (0.0)	1 (1.4)	0 (0.0)	2 (0.6)
Urticaria	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	1 (1.4)	2 (0.6)
Pruritus	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	1 (0.3)
Cardiac disorders	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Cardiac flutter	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)

A treatment-emergent adverse event was defined as any adverse event that occurred for the first time on or after the date of the first dose of double-blind study medication, or existed prior to the first dose date and worsened during the double-blind treatment period.

Table S1. Summary of Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term During the Double-Blind Treatment Period – Safety Population (continued)

System organ class Preferred term	Placebo (N = 71) n (%)	MSDC-0160 50 mg (N = 71) n (%)	MSDC-0160 100 mg (N = 71) n (%)	MSDC-0160 150 mg (N = 70) n (%)	Pioglitazone 45 mg (N = 71) n (%)	Total (N = 354) n (%)
Eye disorders	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Vision blurred	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Infections and infestations	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Urinary tract infection	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Injury, poisoning and procedural complications	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Fall	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Metabolism and nutrition disorders	0 (0.0)	0 (0.0)	1 (1.4)	1 (1.4)	0 (0.0)	2 (0.6)
Hypoglycaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	1 (0.3)
Increased appetite	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Respiratory, thoracic and mediastinal disorders	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	1 (0.3)
Nasal congestion	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	1 (0.3)
Vascular disorders	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	1 (0.3)
Hypertension	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	1 (0.3)

A treatment-emergent adverse event was defined as any adverse event that occurred for the first time on or after the date of the first dose of double-blind study medication, or existed prior to the first dose date and worsened during the double-blind treatment period.